VA HB2233 | 2023 | Regular Session
Status
Spectrum: Partisan Bill (Democrat 1-0)
Status: Introduced on January 11 2023 - 25% progression, died in committee
Action: 2023-02-07 - Left in Commerce and Energy
Pending: House Commerce and Energy Committee
Text: Latest bill text (Prefiled) [HTML]
Status: Introduced on January 11 2023 - 25% progression, died in committee
Action: 2023-02-07 - Left in Commerce and Energy
Pending: House Commerce and Energy Committee
Text: Latest bill text (Prefiled) [HTML]
Summary
Prescription drug price transparency; manufacturer reporting requirements. Removes the requirement that a drug manufacturer submit to the Department of Health's contracted nonprofit data services organization all information included in the manufacturer's annual consolidation report on Securities and Exchange Commission Form 10-K or any other public disclosure in order for the manufacturer's prescription drug reporting obligations to be fully satisfied.
Title
Prescription drug price transparency; manufacturer reporting requirements.
Sponsors
History
| Date | Chamber | Action |
|---|---|---|
| 2023-02-07 | House | Left in Commerce and Energy |
| 2023-01-30 | House | Assigned sub: Subcommittee #4 |
| 2023-01-11 | House | Referred to Committee on Commerce and Energy |
| 2023-01-11 | House | Prefiled and ordered printed; offered 01/11/23 23102980D |
